{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:37Z","timestamp":1790633017407,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejca.2019.01.102","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T05:56:27Z","timestamp":1551765387000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Therapeutic drug monitoring as a tool to optimize 5-FU\u2013based chemotherapy in gastrointestinal cancer patients older than 75 years"],"prefix":"10.1016","volume":"111","author":[{"given":"Pauline","family":"Macaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Morawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Quipourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Marilier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bengrine-Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.tpj.6500476","article-title":"The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer","volume":"8","author":"Capitain","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.ejca.2019.01.102_bib2","doi-asserted-by":"crossref","first-page":"e83196","DOI":"10.1371\/journal.pone.0083196","article-title":"Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer","volume":"8","author":"Qu","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.102_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00000421-198510000-00019","article-title":"Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion?","volume":"8","author":"Lokich","year":"1985","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1989.7.4.425","article-title":"A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study","volume":"7","author":"Lokich","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2019.01.102_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0959-8049(97)00175-5","article-title":"5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer","volume":"33","author":"Rougier","year":"1997","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2019.01.102_bib6","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"Meta-Analysis Group In","year":"1998","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.COC.0000017526.55135.6D","article-title":"Severe toxicity related to the 5-fluorouracil\/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients","volume":"26","author":"Tsalic","year":"2003","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2019.01.102_bib8","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2019.01.102_bib9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2019.01.102_bib10","first-page":"2772","article-title":"Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs","volume":"18","author":"Liu","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.ejca.2019.01.102_bib11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","article-title":"Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity","volume":"12","author":"Amstutz","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.102_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1517\/17425255.2015.1027684","article-title":"Pharmacogenomics of fluorouracil -based chemotherapy toxicity","volume":"11","author":"Matsusaka","year":"2015","journal-title":"Expert Opin Drug Metabol Toxicol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Therapeut"},{"issue":"2","key":"10.1016\/j.ejca.2019.01.102_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-006-0392-5","article-title":"DPYD*2A mutation: the most common mutation associated with DPD deficiency","volume":"60","author":"Saif","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2019.01.102_bib16","first-page":"832","article-title":"Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi Malignancies: experience of 4-years","volume":"23","author":"Saif","year":"2007","journal-title":"Pakistan J Med Sci"},{"issue":"8","key":"10.1016\/j.ejca.2019.01.102_bib17","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2019.01.102_bib18","first-page":"1247","volume":"18","author":"Cai","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"13","key":"10.1016\/j.ejca.2019.01.102_bib19","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.01.102_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/15257770802145009","article-title":"Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene","volume":"27","author":"van Kuilenburg","year":"2008","journal-title":"Nucleos Nucleot Nucleic Acids"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib21","first-page":"224","article-title":"Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?","volume":"9","author":"Ciccolini","year":"2010","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03257473","article-title":"Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy","volume":"51","author":"van Kuilenburg","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2019.01.102_bib25","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics","volume":"50","author":"Paci","year":"2014","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2019.01.102_bib26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer--are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2019.01.102_bib27","first-page":"2039","article-title":"Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00280-003-0658-0","article-title":"Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen","volume":"52","author":"Ychou","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"10.1016\/j.ejca.2019.01.102_bib29","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2019.01.102_bib30","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.18632\/oncotarget.24338","article-title":"5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer","volume":"9","author":"Morawska","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2019.01.102_bib32","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/jco.2014.32.15_suppl.3574","article-title":"Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: U.S.-based clinical practices experience","volume":"32","author":"Braiteh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2019.01.102_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa010957","article-title":"A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients","volume":"345","author":"Sargent","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.102_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-136-5-200203050-00007","article-title":"Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer","volume":"136","author":"Sundararajan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0959-8049(97)00345-6","article-title":"Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis","volume":"34","author":"Etienne","year":"1998","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.102_bib37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0009-9236(95)90171-X","article-title":"Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy","volume":"58","author":"Lu","year":"1995","journal-title":"Clin Pharmacol Therapeut"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib38","first-page":"181","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2019.01.102_bib39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1248\/bpb.28.1071","article-title":"Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharmaceut Bull"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1179\/joc.2010.22.3.179","article-title":"Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer","volume":"22","author":"Duffour","year":"2010","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib41","first-page":"381","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice","volume":"15","author":"Wilhelm","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.102_bib42","first-page":"203","article-title":"Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens","volume":"10","author":"Saam","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N","article-title":"Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial","volume":"75","author":"Stein","year":"1995","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2019.01.102_bib44","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0959-8049(98)00259-7","article-title":"Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group","volume":"34","author":"Zalcberg","year":"1998","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2019.01.102_bib45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1200\/JCO.1999.17.8.2412","article-title":"Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older","volume":"17","author":"Popescu","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.102_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s002800050826","article-title":"Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy","volume":"42","author":"Chiara","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib47","first-page":"1","article-title":"Long-term dental implant success and survival--a clinical study after an observation period up to 6 years","volume":"36","author":"Charyeva","year":"2012","journal-title":"Swed Dent J"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1708-8208.2010.00329.x","article-title":"Fixed implant-supported prostheses in elderly patients: a 5-year retrospective comparison between partially and completely edentulous patients aged 80 years or older at implant surgery","volume":"15","author":"Kowar","year":"2013","journal-title":"Clin Implant Dent Relat Res"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.102_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1186\/s12885-016-2933-6","article-title":"A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors","volume":"16","author":"Chiang","year":"2016","journal-title":"BMC Cancer"},{"issue":"29","key":"10.1016\/j.ejca.2019.01.102_bib50","doi-asserted-by":"crossref","first-page":"20339","DOI":"10.18632\/oncotarget.24861","article-title":"Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD\/FOx regimen, in metastatic gastric cancer","volume":"9","author":"Bruera","year":"2018","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.ejca.2019.01.102_bib51","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.102_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"7","key":"10.1016\/j.ejca.2019.01.102_bib53","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejca.2014.01.005","article-title":"Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer","volume":"50","author":"Jehn","year":"2014","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2019.01.102_bib54","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/cncr.28830","article-title":"Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)","volume":"120","author":"Ulrich","year":"2014","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919301418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919301418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:12Z","timestamp":1760732592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919301418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":54,"alternative-id":["S0959804919301418"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.102","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring as a tool to optimize 5-FU\u2013based chemotherapy in gastrointestinal cancer patients older than 75 years","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}